Skip to main content
MJHS
Navigation
Journal Navigation
Article Navigation
opened article
Volum 30, Issue 4
December 2022
Cover Image

Article contents

opened journal
Volum 30, Issue 4
December 2022
Cover Image

Abstract

Objectives

The objective was to evaluate the relationship of comorbid pathology with the clinical and ultrasound characteristics of the evolution of psoriatic arthritis in order to optimize the management. 

Material and methods

In order to achieve the purpose and objectives of the study, a group of 92 patients with psoriatic arthritis was selected, established in accordance with the CASPAR diagnostic criteria (2006). The patients were treated in the rheumatology and arthrology departments of the Timofei Moşneaga Republican Clinical Hospital and of the Saint Trinity Municipal Clinical Hospital in Chisinau during 2017-2020. A type 1 cohort study is planned (prospective study with retrospective components).

Results

Expression at the time of examination of the history data was observed in 54 (58,7%), clinical enthesitis was observed in 47 (51.1%) patients. During the clinical examination of patients, it was found that the frequency of TJC/14 was 11.3% (145/1288), SJC/14 – 4.5% (58/1288), which was 40% (58/145) among all painful joints. During clinical examination, it was found that the TJC of the upper limbs (74/736, 10.1%) and lower (71/552, 12.9%) do not differ significantly (χ2 = 2.489, p = 0.115). At the same time, the SJC of the lower limbs (43/552, 7.8%) was significantly higher than the upper one (15/736, 2.04%) (χ2 = 24.267, p < 0.001). According to ultrasound data, the number of joints examined was 228/1288 (17.7%), number of inflamed entheses – 90/1288 (6.9%), which was 39.5% among the detected synovitis (90/228). The number of enthesitis were 661/4968 (13.3%), of which 19.4% (128/661) of the entheses were vascularized. 

Conclusions

According to ultrasound data, the frequency of detection of enthesitis and synovitis was significantly higher than during the clinical examination (p < 0.01). For its part, the psoriatic arthritis activity index (DAPSA) did not correlate with inflammatory changes detected during extensive ultrasound of large joints and entheses according to the "gray scale" and the use of Power-Doppler (p > 0.05). On the other hand, vascularization in the entheses is an index of activity independent of age and activity of psoriatic arthritis and psoriasis (p > 0.05), and it is a sign of active inflammation which correlates with laboratory markers of inflammation (hs-CRP, p < 0.05; ESR, p < 0.01).

Key Messages

What is not yet known on the issue addressed in the submitted manuscript

It is not known the relationship between comorbidities and clinical evolution and ultrasound characteristics of psoriatic arthritis, which can help to optimize the tactics of patient management and to appreciate the connection between main syndromes and specific clinical expression.

The research hypothesis

When comparing comorbidities in groups of young and middle-aged patients, it was shown that it was higher in the group of middle-aged patients, but the chronological appearance of comorbidities did not differ, which indicates an increase with age in the number of comorbid diseases pathogenetically associated with the evolution of psoriatic arthritis.

The novelty added by manuscript to the already published scientific literature

During clinical and ultrasound examination of the joints and entheses, it was found that, synovitis was detected significantly more often when using ultrasound, which indicates subclinical synovitis. The frequency of enthesitis in the large joints of the upper and lower extremities according to ultrasound data was 13.3%, which is significantly higher than in the case of a clinical examination (7.7%, p < 0.001), and this indicates asymptomatic enthesitis.

Introduction

Psoriatic arthritis (PsA) is a chronic musculoskeletal and cutaneous inflammatory disease that affects about 20-30% of patients with psoriasis [1, 2]. In addition to musculoskeletal and cutaneous manifestations, patients with PsA have a higher prevalence of comorbidities compared to the general population. More than half of patients with PsA have at least one comorbidity, with up to 40% of patients having more than three comorbidities [2-4]. PsA has a particularly strong association with metabolic diseases and, as a result, with cardiovascular diseases (CVD) [5-6]. There is a higher prevalence of metabolic diseases such as high blood pressure, dyslipidemia, diabetes and obesity compared to patients with psoriasis and without PsA [2, 6-8] or with the general population [2, 5, 9]. PsA is associated with a 55% increased risk of developing CVD, such as ischemic heart disease, cerebrovascular disease, and congestive heart failure [3, 4, 7]. Both, the higher inflammatory burden and the increased incidence and prevalence of traditional CVD risk factors, such as high blood pressure, glucose intolerance, dyslipidemia and obesity in psoriatic disease, seem to play an important role in the development of CVD in PsA [1, 2, 6]. CVD is a major source of morbidity and a leading cause of mortality in PsA [5, 8, 9]. Therefore, addressing these comorbidities can improve quality of life and functional status and reduce healthcare costs as well as mortality in PsA. In this research, we will explore the complex relationship of PsA with metabolic diseases and CVD.

Metabolic syndrome (MetS) is defined by the presence of central obesity, hypertension, insulin resistance, and dyslipidemia [3, 6, 9, 10]. Approximately 24-58% of patients with PsA have MetS, which is higher than that of the general population [4, 7, 9, 11]. In some cohorts that use MetS' NHLBI/AHA validated definition, MetS's prevalence in PsA is up to 59% [6, 9, 11-12]. The chances of having MetS in PsA compared to the general population were 2.68 (CI 95% 1.60 - 4.50) in an outpatient clinic-based study in China [3, 4, 7, 13]. The prevalence of MetS and its components is also usually higher in PsA compared to psoriasis alone: hypertension (37% vs. 20%), hyperlipidemia (21% vs. 15%), diabetes (12% vs. 7%) and obesity (30 vs. 27%) [5, 9, 12]. In addition, there is a higher proportion of patients with MetS PsA compared to rheumatoid arthritis (RA) and other spondyloarthritis (SpA) [3, 7, 8]. MetS prevalence was higher in PsA compared to RA or ankylosing spondylitis (AS) (OR 2.44, CI 95% 1.48–4.01) in an outpatient study of the clinic arthritis. The chances were higher for all components of MetS, including central obesity, decreased blood glucose levels during fasting, hypertriglyceridemia and decreased HDL-C levels [6, 9, 14].

Patients with PsA who are also obese and/or have MetS have been observed to have higher disease activity and weaker treatment results. There may be several reasons for this difference. First, one study found that obese patients tend to have a longer time for diagnosis compared to patients with normal BMI (5.7 vs. 2.8 years). This may be due to the difficulty to examine joints in these patients. Then, obese patients may have worse disease activity reported by patients due to obesity-related functional deficits, and obesity is associated with increased CRP [1-4]. Data from Danish and Icelandic biological registries with 1943 PsA patients also showed higher initial activity of the disease (DAS28, CRP, and visual analog-pain scale) in obese compared to non-obese patients [3, 8, 9].

The purpose of the study was to evaluate the relationship of comorbid pathology with the clinical and ultrasound characteristics of the evolution of psoriatic arthritis in order to optimize the management. 

Material and methods

In order to achieve the purpose and objectives of the study, a group of 92 patients with psoriatic arthritis was selected. The diagnosis of PsA was established in accordance with the CASPAR classification criteria (2006). Patients were treated in the rheumatology and arthrology departments of the Timofei Moşneaga Republican Clinical Hospital and in the Saint Trinity Municipal Clinical Hospital in Chisinau during 2017-2020. A type 1 cohort study is planned (prospective study with retrospective components).

The average age of patients with PsA was 42.9 ± 9.6 years, the average duration of psoriasis was 11 (7; 25.8) years, the average duration of PsA was 7 (2; 11.8) years. Among patients included in the study were 42 men (45.7%) and 50 women (54.3%). Patients’ characteristics are given in table 1.

Table 1. Characteristics of patients with PsA.

Index

Values

Men, n (%) 

Women, n (%)

42 (45.7%)

50 (54.3%)

Age, years, M ± SD, min-max

42.9 ± 9.6, 22-60

Duration of PsA, years, Me (25; 75)

7 (2; 11.8)

DAPSA, Me (25; 75)

15.2 (10.2; 21.4)

Skin psoriasis (Ps), n (%)

91 (98.9%)

Ps duration, years, Me (25; 75)

11 (7; 25.8)

PASI, Me (25; 75)

3.8 (1.2; 9.6)

TJC/14, Me (25; 75)

1 (0; 3)

SJC/14, Me (25; 75)

0 (0; 2)

hs-CRP, mg/l, Me (25; 75)

5.1 (2.2; 16.1)

ESR, mm/h, Me (25; 75)

20 (11; 30)

Note: Ps – psoriasis; PASI - Psoriasis Area Severity Index, TJC - tender joints count; SJC – swollen joints count; M – median; SD – standard deviation; DAPSA - Disease Activity in PSoriatic Arthritis.

A positive family history of psoriasis was detected in 31 (33.7%) patients. At the time of inclusion in the study, 19 (20.6%) patients had disabilities, of which 15 (16.3%) had disabilities due to PsA, and 4 (4.3%) of the patients had a general disease.

Treatment of patients with PsA was carried out in accordance with the recommendations of the National Clinical Protocol „Psoriatic Arthritis in adults” at the time of the study. 

Distribution of patients by PsA activity in calculating the DAPSA (Disease Activity in PSoriatic Arthritis) index: most had moderate activity (14-28) of 33 (42%), high (> 28) in 13 (16%) patients, decreased (4 - 14) – 30 (38%), remission (< 4) was observed in 3 (4%) patients.

The distribution of patients according to the activity of cutaneous psoriasis in the calculation of the PASI index was as follows: remission - 7 (8%), mild - 57 (68%), average - 9 (11%) severe - to 11 (13%) patients.

According to the clinical and instrumental methods of the study, the distribution of patients by the involvement of peripheral joints and spine was as follows: polyarthritis was in 63 (68.5%) patients, oligoarthritis – in 19 (20.7%), monoarthritis – 10 (10.9%), included axial manifestations sacroiliitis – in 30 (32.6%) patients and spondylitis – in 23 patients (25%), a combination of sacroiliitis and spondylitis – in 13 patients (14.1%). Patients with isolated axial lesions were absent.

The areas evaluated in the clinical examination (visual evaluation and determination of pain on palpation) and ultrasonographic areas included similar areas: 

  • Joints (14 in each patient) – acromioclavicular, shoulder, elbow, radiocarpal, hip, knee, talocrural; 

  • Entheses (54 per patient): 

  • The lower pole of the calcaneus: plantar aponeurosis entheses (thickness of the planting aponeurosis ≥4.4 mm; erosion of the lower pole of the calcaneus; enthesophyte of the lower pole of the calcaneus); 

    • Upper pole of the calcaneus: entheses of the Achilles tendon (thickness of the Achilles tendon ≥5.29 mm; retrocalcaneal bursitis; erosion of the posterior pole of the calcaneus; enthesophyte of the posterior pole of the calcaneus); 

    • Tibial tuberosity: distal patellar ligament entheses (thickness of the patellar ligament ≥4 mm; infrapatellar bursitis; erosion of tibial tuberosity; enthesophyte of tibial tuberosity); 

    • Lower pole of the patella: entheses of the proximal patellar ligament; the thickness of the patellar ligament ≥4 mm; erosion of the lower pole of the patella; enthesophyte of the lower pole of the patella); 

    • Upper pole of the patella: entheses of the quadriceps tendon (thickness of the quadriceps tendon ≥6.1 mm; suprapatellar bursitis; erosion of the upper pole of the patella; enthesophyte of the upper pole of the patella); 

    • Tuberosity of the olecranon: triceps tendon entheses (thickness of the triceps tendon ≥4 mm; olecranon bursitis; olecranon erosion; olecranon enthesophyte; olecranon enthesophyte)

Ultrasound modifications of enthesitis were evaluated according to the ultrasound definition of entheses proposed by OMERACT, using a „gray scale” and Power-Doppler to evaluate vascularization (table 2) [5-8].

Table 2. Definition of ultrasound signs of inflammatory and structural changes in entheses (Consensus of experts).

Inflammatory signs (agreement 100%)

Structural features (agreement) 100%)

Localization of the Doppler signal in the entheses 

Calcification/enthesophyte in the entheses 

Hypoechoic entheses

Erosion at the place of attachment 

Thickening of the entheses 

 

Note: Final definition of enthesitis - Hypoechoic and/or thickened tendon at the site of insertion on the bone (on the bone at 2 mm), with Doppler signal for active entheses and the presence of erosions and enthesophytes/calcified as a sign of structural damage.

Ultrasound included counting the following signs: 

  • in the „gray scale” mode: the number of joints with ultrasound signs of synovitis (the number of synovitis), the number of joints with osteophytes; 

  • in Power-Doppler mode: the number of joints with ultrasound signs of active synovitis (number of vascularized synovitis); 

  • number of affected entheses: decrease in echogenicity and thickening of the entheses, number of entheses with the presence of vascularization, number of entheses with structural changes: the presence of erosions, enthesophytes, calcifications. 

Taking into account the identified changes, the following ultrasound indices were calculated: GUESS (Glasgow Ultrasound Enthesitis Scoring System), BUSES (Belgrade Ultrasound Enthesitis Score), MASSI (Madrid Sonography Enthesitis Index) and SEI (Sonographic Enthesitis Index).

Results

The patients included in the study were clinically examined and an ultrasound of large joints and entheses were performed (the total number of joints examined was 1288, entheses – 4968).

Expression at the time of examination of the history data was observed in 54 (58,7%), clinical enthesitis was observed in 47 (51.1%) patients. During the clinical examination of patients, it was found that the frequency of TJC/14 was 11.3% (145/1288), SJC/14 – 4.5% (58/1288), which was 40% (58/145) among all painful joints.

During clinical examination, it was found that the TJC of the upper limbs (74/736, 10.1%) and lower (71/552, 12.9%) do not differ significantly (χ2 = 2.489, p = 0.115). At the same time, the SJC of the lower limbs (43/552, 7.8%) was significantly higher than the upper one (15/736, 2.04%) (χ 2 = 24.267, p < 0.001).

It should be noted that pain and swelling of the hip joints could not be determined by physical examination; therefore, they were not taken into account in this analysis. TJC/14 and SJC/14 in terms of localization were as follows: acromioclavicular joints - 5 and 0, shoulder - 29 and 2, elbow - 13 and 1, hand joints - 29 and 15, knees - 38 and 25, talocrural - 33 and 18 respectively.

When assessing the involvement of entheses in the projection of large joints, it was found that the number of painful entheses of the upper extremities (71/1472, 4.8%) was significantly lower than the lower ones (310/3496, 8.9%) (χ2 = 23,923, p < 0.001). The localization of painful entheses on palpation was as follows: at the place of attachment of the supraspinous muscle - 7, the subosteal muscle - 1, the subscapular muscle - 1, the triceps muscle - 2, at the lateral epicondyle - 35, at the medial epicondyle - 25, at the anterior spines of the iliac bones (upper and lower) - 37, at the posterior spines of the iliac bones - 11, at the sciatic tubercle - 1, in the large trochanter - 5, the medial collateral ligament: proximal section - 16, distal - 25, the lateral collateral ligament: proximal section - 26, distal section - 23, quadriceps muscle - 7, semimembranosus muscle - 8, anterior muscle - 5, posterior muscle - 6, Achilles tendon - 38, plantar fascia - 9.

According to ultrasound data, the number of joints examined was 228/1288 (17.7%), the number of inflamed entheses – 90/1288 (6.9%), which was 39.5% among the detected synovitis (90/228). The number of entheses was 661/4968 (13.3%), of which 19.4% (128/661) of the entheses were vascularized. The number of confirmed was 876/4968 (17.6%). The frequency of enthesitis and synovitis detected in the gray scale mode according to ultrasonographic data is shown in table 3.

Table 3. Frequency of enthesitis and synovitis detected in the "grayscale" mode according to ultrasonographic data.

Upper limbs

Frequency

Lower limbs

Frequency

Joints:

Acromio-clavicular

46/736 (6.3%)

Coxofemural

28/552 (5.1%)

Humeral

7/736 (0.95%)

Knee

42/552 (7.6%)

Ulnar

18/736 (2.4%)

Talocrural

32/552 (5.8%)

Radiocarpal

47/736 (6.4%) 

Total

118/736 (16%)

Total

112/552 (20.3%)*

Enthesitis:

Short head of the biceps muscle of the shoulder

10/1472 (0.7%)

Great trochanter: 

- gluteus minor

- gluteus medium 

28/3496 (0.8%)

45/3496 (1.3%)

Subscapular muscle

20/1472 (1.4%)

Sciatic tubercle

28/3496 (0.8%)

Nastular muscle

13/1472 (0.9%)

Collateral ligament medial 

- proximal

- distal

 

53/3496 (1.5%)

20/3496 (0.6%)

Subosteal muscles 

2/1472 (0.1%)

Lateral collateral ligament:

- proximal

- distal

 

33/3496 (0.9%)

19/3496 (0.5%)

Triceps muscle of the shoulder

11/1472 (0.7%)

Own patellar ligament 

- proximal 

- distal

6/3496 (0.2%)

21/3496 (0.6%)

Medial epicondyle

30/1472 (2%)

”Pes anserinus mirror”

70/3496 (2%)

Lateral epicondyle 

54/1472 (3.7%)

Femoral biceps

9/3496 (0.3%)

 

 

Semi-membranous muscles

36/3496 (1%)

 

 

Quadriceps femoral

23/3496 (0.7%)

 

 

Anterior tibial muscle

19/3496 (0.5%)

 

 

Posterior tibial muscle

18/3496 (0.5%)

 

 

Achilles

27/3496 (0.8%)

 

 

Plantar fascia

43/3496 (1.2%)

Total

144/1472 (9.8%)

Total

517/3496 (14.8%)**

Note: *p < 0.05, **p < 0.01.

     

When evaluating the differences in the frequency of synovitis of the lower (112/552, 20.3%) and superior (118/736, 16%) limbs, it was found that the synovitis of the lower extremities was significantly more frequent (χ2 = 3.897, p < 0.05).

When evaluating the differences in the frequency of enthesitis, it was found that enthesitis of the lower extremities (517/3496, 14.8%) occurred significantly more often than the upper one (144/1472, 9.8%, χ2 = 22.502, p < 0.001).

The changes detected in the „gray scale” mode can be a sign not only of an active process, but also of chronic inflammation, therefore the presence of vascularization of synovitis and enthesitis, detected with the help of Power-Doppler, is more likely to indicate the activity of the process. Comparing the frequency of vascularization of large joints of the upper and lower extremities is not possible, since piloting the Doppler signal during inflammation of the hip and talocrural joints is difficult due to the anatomical features of these joints.

In the study it was found that the frequency of enthesitis detected during the clinical examination was 7.7% (the number of painful entheses, 381/4968) compared to 13.3% according to the ultrasound data (the number of entheses, 661/4968), which was significantly lower (p < 0.001).

When comparing ultrasound data in the groups of patients with isolated peripheral arthritis (n = 52) and in combination with axial lesions (n = 40), no differences were found in groups (number of synovitis (by ultrasound examination), number of enthesitis, number of entheses with structural disorders, number of vascular Doppler-positive entheses, GUESS, BUSES, SEI, MASSI, p > 0.05). DAPSA scores were significantly higher in the group of patients with a combination of peripheral arthritis with spinal injuries (p < 0.01). The groups were different in terms of duration of PsA (p = 0.013), severity of psoriatic onychodystrophy (NAPSI, p < 0.01), TJC/14 (p = 0.037) and CRP-hs (p = 0.031) and were higher in the group of patients with peripheral arthritis and axial involvement.

Discussions

It is known that spondyloarthritis mainly affects the joints and entheses of the lower extremities, therefore, in most cases; the entheses of the lower extremities were included in various clinical indices of enthesitis. In this study, during an extensive clinical examination and ultrasound of the joints and entheses of the upper and lower extremities, depending on the „gray scale”, it was shown that the frequency of synovitis of the lower limbs (20.3%) was significantly higher than the upper one (16%) (p < 0.05), and the entheses of the lower extremities (14.8%) were observed significantly more often than the upper part (9.8%), (p < 0.001), which corresponds to the literature data [6, 10, 13]. The identified differences can be explained by the higher frequency of trauma of the enthesis of the lower extremities, which, according to the theory of biomechanical stress, is one of the triggers for the development of enthesitis [2, 8, 11, 14]. However, this has not been demonstrated for vascularized entheses, the frequency of which does not differ according to location (p > 0.05).

Despite the low incidence of obesity (25%), it should be noted a higher frequency of overweight patients (33.3%), as well as an increase in the ratio of chest circumference to body circumference (57.1%), which should also be taken into account. With the increase in thoracic circumference, body circumference and BMI of the patient, the number of comorbid conditions increased significantly (p < 0.01). Several directions of research are needed to examine the link between PsA and obesity to further determine whether obesity is a consequence of PsA. Other potential mechanisms linking obesity in PsA and cardiovascular risk (dyslipidemia, high blood pressure, insulin resistance, and smoking) have not yet been identified. The effect of obesity on the activity of PsA and the response to DMARD therapy and TNFα inhibitors [6, 11-13] has been demonstrated, in addition, weight loss has contributed to a decrease in the severity of joint and entheses inflammation, as well as in the activity of skin psoriasis [4, 6, 9].

When comparing comorbidities in groups of young and middle-aged patients, it was shown that comorbidity was higher in the group of middle-aged patients (p < 0.05), and chronological comorbidities (p > 0.05) in groups does not differ, which indicates an increase with age mainly in the number of comorbid diseases pathogenetically associated with the course of PsA. The presence of axial lesions in patients with peripheral arthritis did not increase the number of comorbid diseases in patients with PsA (p > 0.05).

In this case, patients with peripheral arthritis and spinal cord injury had a longer duration of PsA (p = 0.013), severity of psoriatic onychodystrophy (NAPSI, p < 0.01), PsA activity (DAPSA), TJC/14 (p < 0.05) and higher levels of hs-CRP (p < 0.05) compared to patients with isolated peripheral arthritis. Interestingly, ultrasonographic parameters of joint and entheses lesions do not differ.

During the clinical examination carried out and the ultrasound of the joints and entheses, it was found that synovitis (17.7%) was detected significantly more often than with the help of a clinical examination (TJC/14 and SJC/14, 4.7% and 11.3%, p < 0.01), which indicates subclinical synovitis. The frequency of entheses in the large joints of the upper and lower extremities according to ultrasound data was 13.3%, which is significantly higher than in the case of a clinical examination (7.7%, p < 0.001), and this also indicates asymptomatic entheses, a finding consistent with the literature [4-7, 9-12].

The higher frequency of detection of pathological changes according to ultrasound data compared to a clinical examination is a serious reason for an extensive evaluation of the ultrasound signs of inflammation and joint entheses - its nature and localization - and the determination of their role in patient management.

Conclusions

  1. According to ultrasound data, the frequency of detection of enthesitis and synovitis were significantly higher than during the clinical examination (p < 0.01). In turn, the activity index PsA (DAPSA) did not correlate with the inflammatory changes detected during the extensive ultrasound of large joints and entheses according to the „gray scale” and with the use of Power-Doppler (p > 0.05). 

  2. Vascularization in the entheses is an index of activity independent of age and activity of PsA and psoriasis (p > 0.05) a sign of active inflammation with correlation with laboratory markers of inflammation (hs-CRP p < 0.05, ESR p < 0.01). At the same time, the SMI technique demonstrated comparable results with Power-Doppler in identifying the frequency of vascularized synovitis of large joints (52.6% vs 44.4%, p > 0.05); when assessing entheses vascularization, the frequency of SMI+ vascularized entheses were significantly higher than Power-Doppler+ (33.3% vs. 17.1%, p < 0.001). 

Abbreviations

AS – Ankylosing Spondylitis; BMI – body mass index; BUSES – Belgrade Ultrasound Enthesitis Score; CASPAR – The ClASsification for Psoriatic Arthritis; CI – Confidence Interval; CVD – cardiovascular diseases; DAPSA – Disease Activity in PSoriaticArthritis; DAS-28 – Disease Activity Score; DMARD – Disease-modifying antirheumatic drugs; ESR – erythrocyte sedimentation rate; GUESS – Glasgow Ultrasound Enthesitis Scoring System; hs-CRP – high sensitivity C-reactive protein; M – median; MASSI – Madrid Sonography Enthesitis Index; MetS – metabolic syndrome; NAPSI – Nail Psoriasis Severity Index; NHLBI/AHA – National Heart; Lung; and Blood Institute / American Heart Association; OR – Odds Ratio; PASI – Psoriasis Area Severity Index; Ps – psoriasis; PsA – psoriatic arthritis; RA – rheumatoid arthritis; SD – standard deviation; SEI – Sonographic Enthesitis Index; SJC – swollen joints count; SpA – Spondyloarthritis; TJC – tender joints count; TNFα – Tumor Necrosis Factor-α.

Competing interests

None declared

Authors’s ORCID ID 

Lucia Dutca, https://orcid.org/0000-0002-1815-2294

References

  1. Groppa L., Popa S., Rotaru L. et al. Rheumatology and nephrology. Textbook. Lexon Prim, Chișinău, 2019. 462 p. ISBN 978-9975-3344-1-9.

  2. Protocolul Clinic Național – Artrita psoriazică la adult, PNC-295, Chișinău, 2018 (msmps.gov.md/wp-content/uploads/2020/07/15584-PCN-29520Artrita20psoriatica20la20adult.pdf).

  3. Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014; 73:1012–9. doi: 10.1136/annrheumdis-2014-205207.

  4. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54:2665–73.  doi: 10.1002/art.21972.

  5. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2019 Sep;68(9):1387- 94.  doi: 10.1136/ard.2008.094946

  6. Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of the WHO international classification of functioning, health, and disability. Curr Rheumatol Rep. 2021; 14:369–374. doi: 10.1007/s11926-012-0263-5.

  7. Kalyoncu U, Ogdie A, Campbell W, et al. Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open. 2016; 2:e000217.  doi: 10.1136/rmdopen-2015-000217. 

  8. World Health Organization. International Classification Of Functioning, disability and health (ICF) [Internet]; [cited 2017 Dec 2]. Available from: www.who.int/classifications/icf/en/.&nbsp;

  9. Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustün B, Stucki G. ICF linking rules: an update based on lessons learned. J Rehabil Med. 2020; 37:212-8. doi: 10.1080/16501970510040263.

  10. Stucki G, Cieza A, Geyh S, Battistella L, Lloyd J, Symmons D, et al. ICF Core Sets for rheumatoid arthritis. J Rehabil Med 2020;44 Suppl:87-93. doi: 10.1080/16501960410015470.

  11. Boonen A, Braun J, van der Horst Bruinsma IE, Huang F, Maksymowych W, Kostanjsek N, et al. ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis. 2019; 69:102-7. doi: 10.1136/ard.2008.104117.

  12. van Echteld I, Cieza A, Boonen A, Stucki G, Zochling J, Braun J, et al. Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol. 2017; 33:2475-83. Epub 2006 Oct 15. PMID: 17013999.

  13. Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN; Psoriasis Patient Interview Study Group. A multicenter, non-interventional study to evaluate patientreported experiences of living with psoriasis. J Dermatolog Treat. 2016; 27:19-26. doi: 10.3109/09546634.2015.1044492. 

  14. Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014 Aug 17;20(8):13030/qt48r4w8h2. PMID: 25148272. 

More articles

Research Clinical patterns and complete blood count parameters in young patients with primary myelofibrosis in the prefibrotic stage
Nina Sghibneva-Bobeico1,2*, Vasile Musteata1,2, Maria Robu1,2, Lidia Jalba1, Larisa Musteata2, Ala Dorogan1, Cristina Dudnic1, Elena Covalschi1
https://doi.org/10.52645/MJHS.2022.4.04
Primary myelofibrosis is a rare myeloproliferative neoplasm that affects 0.2-1.5 people per 100,000. As a rule, the diagnosis is confirmed after 60 years, but recently, hematologists around the world have encountered the problem of primary myelofibrosis in young people. The classic manifestations of myelofibrosis are characterized by splenomegaly, cytopenia, and bone marrow fibrosis, but in patients younger than 40 years, the diagnosis is most often made in the prefibrotic stage of the neoplasm. The aim of the paper is to identify and evaluate the clinical and hematological features of primary myelofibrosis in young patients in the prefibrotic stage.
Research Predisposing factors for surgical complications in chronic prostatitis and fibrosis of the prostate
Artur Colța*†, Vitalii Ghicavîi†
https://doi.org/10.52645/MJHS.2022.4.05
Prostatitis is an inflammatory process of the prostate, which continues to be considered one of the most common urological diseases in men under 45. Predisposing factors such as trophic, microcirculatory, and congestive disorders contribute to the onset and development of the inflammatory process in the prostate, as do risk factors such as the urethral catheter, urethrocystoscopy, endoscopic surgery for infection, and deterioration of the integrity of the urethral epithelium. The purpose of this study was to determine the impact of chronic inflammation and fibrosis of the prostate on urodynamics and local prostatic microcirculation and to evaluate the efficacy of conservative treatment.
Research Contemporary surgical options in large benign prostatic hyperplasia treatment
Alexei Plesacov1,2†*, Ivan Vladanov1,2†, Vitalii Ghicavii1,2†
https://doi.org/10.52645/MJHS.2022.4.06
Specialists are currently interested in the method of choice for surgical treatment in patients with enlarged benign prostate hyperplasia (> 80 cm3). The introduction of laser and bipolar technologies for benign prostate hyperplasia surgery has allowed effective treatment regardless of the size of the prostate gland.
Research Impact of drainage technique on surgical treatment of ureteropelvic junction obstruction in adults
Urinary drainage is a key part of ureteropelvic junction obstruction treatment. Both external and internal drainage methods have been widely used for many years, but there is now relevant research comparing these methods and their impact on surgical outcomes in adults. The aim of the current research was to assess the efficacy and safety of two different types of urinary drainage on adult pyeloplasty.
Research Risk management - component part of the quality assurance system of pharmaceutical care
Nicoleta Cheptanari-Birta*†, Stela Adauji†, Mihail Brumărel†
https://doi.org/10.52645/MJHS.2022.4.09
In the pharmaceutical field, the quality management is a priority and the risk management is a valuable component of an effective quality system. It involves anticipating hazards and controlling risk through a process of risk awareness, reduction, and review. The aim of this paper was to reveal the usefulness of modern risk management strategies and to assess the impact of risk management in the provision of quality services by community pharmacies.
Research Epidemiological data and diagnosis pitfalls in aggressive extranodal non-Hodgkin’s lymphomas: current issues
Dumitrita Urescu1,2*, Vasile Musteața1,2, Nina Sghibneva-Bobeico1,2, Maria Robu2, Larisa Musteața2, Victor Munteanu1
https://doi.org/10.52645/MJHS.2022.4.10
Non-Hodgkin's lymphoma is a group of malignant tumors that develop from hematopoietic cells located outside the medullary. They are one of the most common forms of hemoblastosis. Non-Hodgkin lymphoma develops in people of all ages. Morbidity of non-Hodgkin lymphoma increases with age reaching its highest level in people over 50 years of age.
Case study Osteitis condensans ilii – difficulty in diagnosis and management. Clinical case study
Liliana Groppa1,2†, Marinela Homițchi1†, Valeria Stog1†, Eugeniu Russu1*†, Lia Chișlari1†, Oxana Bujor2,3†, Lilea Taran3†
https://doi.org/10.52645/MJHS.2022.4.11
Osteitis condensans ilii (OCI) is a condition characterized by benign sclerosis of the iliac bone in the portion adjacent to the sacroiliac joints, which is radiologically manifested by triangular opacities at the level of this portion. Among the clinical manifestations, localized low back or lumbosacral pain is often attested, which is found in the gestational or post-partum period. The pain may worsen during physical exertion or during menstruation and may be accompanied by myalgia.
Case study Pathogenetic correlation of severe sepsis and multiple organ dysfunction syndrome provoked by multiple infections in perinatal period of women
Luminita Mihalcean1*†, Victoria Rotaru2†, Elena Titica2†
https://doi.org/10.52645/MJHS.2022.4.12
Despite significant advances in diagnosis, medical management and antimicrobial therapy, sepsis in the puerperium remains an important cause of maternal morbidity and mortality. The abnormalities associated with the clinical syndrome of sepsis result from a nonspecific innate inflammatory response. This is due to the fact that sepsis represents a systemic inflammatory response syndrome (SIRS) to infection or injury; therefore, it can rapidly progress to septic shock and death despite aggressive treatment.
Case study Osteomyelitis of the jaws and facial bones caused by drug use (amphetamine, α- pyrrolidinovalerophenone)
Natalia Rusu-Radzichevici
https://doi.org/10.52645/MJHS.2022.4.13
An attempt was made to detect the pathogenetic factors involved in the occurrence of the disease by studying the clinical and laboratory data of 160 patients diagnosed with chronic osteomyelitis of the jaws treated in the clinic of oro-maxillo-facial surgery between 2005 and 2022. The patients studied were or are still drug users who use illicitly produced (amphetamine-type drugs) or other drugs (abbreviated α-PVP).